Gusto Global is a biotechnology company developing live biotherapeutic products and microbiome-based diagnostics. Its therapeutic pipeline includes GUT-108, a defined bacterial consortium for inflammatory bowel disease, and GUT-115, a candidate designed to enhance immune-checkpoint response in oncology patients. The company also runs Tapestry, a fragment-sequencing test that analyzes microbial cell-free DNA in blood for non-invasive disease detection.
Founded in 2015 in North Carolina, Gusto Global emerged from technology licensed by University of Chicago researchers Jack Gilbert and John Alverdy. The company operates the GUST+ bioinformatics platform combining microbial ecology, metagenomics, and machine learning, and conducts research collaborations with the Crohn's and Colitis Foundation, the University of North Carolina, and the National Institutes of Health.
